Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Tocilizumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG108

    Antineoplastic and Immunomodulating Agents - Tocilizumab Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG108 alerts

    Get alerted when Policy CG108 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-benefit exceptions for non-preferred intravenous tocilizumab products and continued intravenous Tyenne use. It applies to members requesting physician-administered tocilumab products when preferred-product and subcutaneous formulation requirements may not be met.

    Policy Summary
    PayerOscar Health
    PolicyTocilizumab Products: Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG108
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionUse Tyenne subcutaneous injection first before requesting IV tocilizumab, unless a qualifying exception is met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Tocilizumab IV products listed in the medical preferred drug table
    12 monthsMaximum standard authorization period when exception criteria are met
    3 monthsInitial authorization period for shortage or unavailability exceptions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6
    Exception pathways for continued IV Tyenne
    4Applicable HCPCS billing codes

    Coverage Criteria

    Non-preferred Product Exception

    Coverage for a non-preferred product will be provided when ALL of the following are met.

    Non-preferred product exception

    • ONE qualifying exception pathway

      • Preferred-product failure: Inadequate response or treatment failure with the preferred product(s).
      • Preferred-product unavailable: Drug shortage or unavailability of the preferred product.
      • Intolerable adverse event: The member experienced an intolerable adverse event with the preferred product, and the event is not an expected adverse event attributable to the active ingredient, such as a known adverse reaction shared by reference and biosimilar products.
      • Preferred-product contraindication: The member has a contraindication to the preferred product that would not exist or be reasonably expected with the requested non-preferred product, such as hypersensitivity to specific excipients.
      • Lack of approval or appropriateness: The preferred product has not received FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member’s diagnosis.
      • Dosing or administration limitation: The required dosing or administration cannot be achieved using the preferred product.
      • Evidence-supported preference: Clinical evidence or current treatment guidelines support preferential use of the requested product over all preferred products for the requested therapy regimen.
      • State-law cancer exception: The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.
    • SC formulation response requirement: The member has inadequate response or treatment failure to the subcutaneous formulation, as applicable.
    • Clinical documentation is provided to support the exception request.

      Examples include notification of drug shortage or unavailability, specific details of inadequate response or treatment failure, the nature and severity of adverse events, and specific contraindications.

    Continued IV Tyenne

    Continued IV Tyenne will be authorized when ONE of the following criteria is met.

    ONE qualifying continued-IV exception

    • SC contraindication: The member has a documented contraindication to the subcutaneous formulation of Tyenne that would not be expected to occur with the IV formulation.
    • SC intolerable adverse event: The member experienced a documented intolerable adverse event with the subcutaneous formulation of Tyenne that would not be expected to occur with the IV formulation.
    • Administration limitation: The member has physical or cognitive limitations that prevent subcutaneous self-administration or administration by a caregiver, including visual impairment, limited manual dexterity, or impaired cognitive function.

      Documentation is required.

    Non-preferred tocilizumab products are not covered when used for experimental, investigational, unproven, or medically unnecessary indications. This includes unsupported non-FDA-approved or off-label use, excessive dosing without sufficient evidence, use that is not required to treat or manage the member’s condition, use inconsistent with generally accepted medical practice, or use primarily for the convenience of the member, family, or provider.

    Use is considered medically unnecessary when it is not required for treatment or management of the member’s medical condition, is not aligned with generally accepted medical practice, or is primarily for convenience. Requests may also be considered unproven when the indication is outside FDA-approved labeling or is not supported by current medical evidence and standards of care, including unsupported off-label use or dosing beyond the FDA-approved label or clinical practice guidelines.

    Initial Therapy Criteria

    Initial Non-preferred Product Exception

    A non-preferred product is covered when ALL of the following criteria are met.

    Initial non-preferred product exception

    • ONE qualifying exception pathway

      • Preferred-product failure: Inadequate response or treatment failure with the preferred product(s).
      • Preferred-product unavailable: Drug shortage or unavailability of the preferred product.
      • Intolerable adverse event: The member experienced an intolerable adverse event with the preferred product, and the event is not an expected adverse event attributable to the active ingredient, such as a known adverse reaction shared by reference and biosimilar products.

    Continuation Criteria

    Continued IV Tyenne

    The Plan will authorize continued IV Tyenne when ONE of the following criteria is met.

    ONE qualifying continued-IV exception

    • SC contraindication: The member has a documented contraindication to the subcutaneous formulation of Tyenne that would not be expected to occur with the IV formulation.
    • SC intolerable adverse event: The member experienced a documented intolerable adverse event with the subcutaneous formulation of Tyenne that would not be expected to occur with the IV formulation.
    • Administration limitation: The member has physical or cognitive limitations that prevent subcutaneous self-administration or administration by a caregiver, including visual impairment, limited manual dexterity, or impaired cognitive function.

      Documentation is required.

    Preferred Formulation Requirement

    StepRequired therapyException criteria
    1Use Tyenne (tocilizumab-aazg) subcutaneous injection first before requesting IV Tyenne, IV Actemra (tocilizumab), IV Avtozma (tocilizumab-anoh), or IV Tofidence (tocilizumab-bavi).The subcutaneous-first requirement may be bypassed when at least one continued-IV Tyenne exception applies: contraindication or intolerable adverse event specific to SC Tyenne that would not be expected with IV; physical or cognitive limitation preventing SC administration; significantly impaired SC absorption; lack of FDA approval, evidence-based guideline support, or clinical appropriateness for the SC formulation; or a dose unavailable, infeasible, or inadvisable for SC administration.

    Authorization Duration

    Non-preferred tocilizumab authorization
    Standard authorizationUp to 12 months when all applicable prior authorization criteria are met.
    Drug shortage or unavailabilityInitial approval is limited to 3 months.
    ExtensionThe authorization may be extended only with continued documentation of the shortage or unavailability.
    Continued IV Tyenne authorization
    Authorization durationUp to 12 months when a continued-IV exception criterion is met.
    Exception requirementAt least one criterion supporting continued IV Tyenne must be met.
    Examples of qualifying criteria

    Applicable Billing Codes

    CPT/HCPCS Codes considered medically necessary if criteria are metHCPCSCovered
    J3262Actemra IV Injection, tocilizumab, 1 mg
    Q5135Tyenne IV Injection, tocilizumab-aazg (Tyenne), biosimilar, 1 mg
    Q5133Tofidence IV Injection, tocilizumab-bavi (Tofidence), biosimilar, 1 mg
    Q5156Avtozma IV Injection, tocilizumab-anoh (Avtozma), biosimilar, 1 mg

    Prior Authorization and Submission Guidance

    Prior Authorization

    Non-Preferred Product Exception Review

    Submit prior authorization for a non-preferred Tocilizumab product and document that the member meets the Plan’s applicable preferred-drug exception criteria. An exception may be supported by inadequate response or treatment failure, shortage or unavailability, a qualifying intolerance or contraindication, lack of appropriate FDA approval or evidence-based support, inability to achieve required dosing or administration, evidence favoring the requested product, or cancer-treatment regulations prohibiting prerequisite trials.

    • The member must meet one applicable exception pathway.
    • The request must also meet the applicable Tyenne subcutaneous prerequisite and include supporting clinical documentation.
    Prior Authorization

    Authorization Duration

    When all prior authorization criteria are met, the requested non-preferred product may be authorized for up to 12 months. Requests based on a drug shortage or unavailability receive an initial approval of 3 months and may be extended only with continued documentation; if the shortage resolves, transition to the preferred product may be required at the next authorization period.

    Policy Background

    For physician-administered tocilizumab, Tyenne (tocilizumab-aazg) IV is the preferred medical-benefit product. Actemra IV, Avtozma IV, and Tofidence IV are non-preferred products and require an approved exception determination. Members requesting IV Tyenne or another IV tocilizumab product are generally expected to use Tyenne subcutaneous injection first, unless a qualifying exception for continued or requested IV therapy is documented.

    Key Definitions

    Contraindication
    DefinitionA pre-existing condition or factor that precludes use of a drug because of risk of harm.
    ApplicationA contraindication to the preferred product may support an exception when it would not exist or reasonably be expected with the requested non-preferred product.
    ExampleHypersensitivity to specific excipients.
    Intolerance
    DefinitionThe inability to tolerate or endure a medication or treatment because of difficult or harmful side effects, reactions, or hypersensitivities.
    Treatment impactThe effects negatively impact quality of life, ability to adhere, or overall health.

    Preferred and Non-Preferred Products

    Billing Rule

    Follow the tocilizumab IV product hierarchy

    Tyenne IV is the preferred physician-administered tocilizumab product. Actemra IV, Avtozma IV, and Tofidence IV are non-preferred and require a Plan exception determination; use the applicable HCPCS code for the product requested.

    Policy Summary
    PayerOscar Health
    PolicyTocilizumab Products: Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG108
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionUse Tyenne subcutaneous injection first before requesting IV tocilizumab, unless a qualifying exception is met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaPreferred Formulation RequirementAuthorization DurationApplicable Billing CodesPrior Authorization and Submission GuidancePolicy BackgroundKey DefinitionsPreferred and Non-Preferred Products
    Impaired SC absorption:
    The member has a documented medical condition that significantly impairs subcutaneous absorption, making IV administration necessary for effective treatment.
  1. SC lack of approval or appropriateness: The subcutaneous formulation has not received FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member’s diagnosis.
  2. SC dosing limitation: The member requires a dose that is not available, feasible, or advisable for subcutaneous administration.
  3. Preferred-product contraindication: The member has a contraindication to the preferred product that would not exist or be reasonably expected with the requested non-preferred product, such as hypersensitivity to specific excipients.
  4. Lack of approval or appropriateness: The preferred product has not received FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member’s diagnosis.
  5. Dosing or administration limitation: The required dosing or administration cannot be achieved using the preferred product.
  6. Evidence-supported preference: Clinical evidence or current treatment guidelines support preferential use of the requested product over all preferred products for the requested therapy regimen.
  7. State-law cancer exception: The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.
  8. SC formulation response requirement: The member has inadequate response or treatment failure to the subcutaneous formulation, as applicable.
  9. Clinical documentation is provided to support the exception request.

    Examples include notification of drug shortage or unavailability, specific details of inadequate response or treatment failure, the nature and severity of adverse events, and specific contraindications.

  10. Impaired SC absorption: The member has a documented medical condition that significantly impairs subcutaneous absorption, making IV administration necessary for effective treatment.
  11. SC lack of approval or appropriateness: The subcutaneous formulation has not received FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member’s diagnosis.
  12. SC dosing limitation: The member requires a dose that is not available, feasible, or advisable for subcutaneous administration.
  13. A contraindication or intolerable adverse event with the subcutaneous formulation that would not be expected with IV, or a physical or cognitive limitation preventing subcutaneous administration.
    • Standard authorization duration: up to 12 months.
    • Shortage or unavailability exception: 3-month initial authorization, subject to continued documentation.
    Step Therapy

    Tyenne Subcutaneous First

    Use Tyenne (tocilizumab-aazg) subcutaneous injection first before requesting Tyenne IV, Actemra IV, Avtozma IV, or Tofidence IV, unless a qualifying exception for continued IV Tyenne applies.

    • The SC-first requirement applies to all listed IV Tocilizumab products.
    • A qualifying exception must be documented when the SC prerequisite cannot be met.
    Documentation Required

    Supporting Clinical Documentation

    Include clinical documentation that supports both the diagnosis and the requested exception. Records should be current and specific to the request, rather than relying only on a medication order.

    • Up-to-date chart notes, relevant test results, and/or imaging reports.
    • Prescription information, claims records, or receipts supporting prior alternative trials.
    • For exceptions, provide details such as shortage or unavailability, inadequate response or treatment failure, adverse-event nature and severity, or the specific contraindication.
    Documentation Required

    Documentation for Continued IV Tyenne

    For continued IV Tyenne, document the specific reason the member cannot use the SC formulation and why IV administration is appropriate. Documentation is required for physical or cognitive limitations and should substantiate any contraindication, intolerable adverse event, absorption problem, diagnosis-related limitation, or dosing issue.

    • Documented contraindication to SC Tyenne not expected with IV Tyenne.
    • Documented intolerable SC adverse event not expected with the IV formulation.
    • Physical or cognitive limitation preventing self-administration or caregiver administration, such as visual impairment, limited manual dexterity, or impaired cognitive function.
    • Medical condition significantly impairing SC absorption; SC formulation not FDA-approved, evidence-supported, or clinically appropriate; or a dose not available, feasible, or advisable for SC administration.
    Denial Risk

    Failure to Meet Exception Criteria

    Requests may be denied when the preferred-product exception requirements are not satisfied. A non-preferred product requires an applicable exception, the required SC formulation review, and adequate clinical support before authorization can be granted.

    • Failure to document trial and failure, inadequate response, qualifying intolerance or contraindication, or another permitted exception pathway may result in denial.
    • Missing or insufficient clinical documentation may result in denial.
    • For shortage-based requests, failure to provide continued proof of shortage or unavailability may prevent extension.
    Denial Risk

    SC Formulation Prerequisite

    Requests for IV Tyenne, Actemra, Avtozma, or Tofidence may be denied without prior Tyenne SC use unless the request documents a qualifying exception to the SC requirement. The exception must be relevant to the member’s condition and supported by clinical records.

    • Do not bypass the Tyenne SC prerequisite without documenting a qualifying contraindication, intolerance, functional limitation, impaired absorption, lack of appropriate approval or evidence, diagnosis-related inappropriateness, or infeasible SC dose.
    • Functional or cognitive limitations require supporting documentation.
    Denial Risk

    Unproven or Medically Unnecessary Use

    Non-preferred products are not covered for experimental, investigational, unproven, or medically unnecessary use. Avoid submitting requests for indications outside FDA-approved labeling or unsupported by current medical evidence and standards of care.

    • Off-label or non-FDA-approved use without sufficient evidence supporting safety and efficacy.
    • Doses exceeding FDA labeling or clinical guidelines without sufficient supporting evidence.
    • Use not required to treat or manage the condition, not aligned with generally accepted medical practice, or primarily for member, family, or provider convenience.
    Documentation expected
    Documentation should detail the specific intolerable effects and their impact on treatment.
    Documentation
    DefinitionWritten information used to support diagnoses and prior trials of alternatives.
    Clinical recordsUp-to-date chart notes, relevant test results, and relevant imaging reports may support diagnoses.
    Medication recordsPrescription claims records and prescription receipts may support prior trials of alternatives.
    Medical Benefit Preferred Drug Exceptions Criteria
    DefinitionPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Preferred-drug requirementRequirements may include trying preferred drugs first.
    Failure of preferred drugsThe criteria may require trial and failure of preferred drugs before approval of the non-preferred drug.